{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:42:00Z","timestamp":1792510920777,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,6,14]],"date-time":"2020-06-14T00:00:00Z","timestamp":1592092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,14]],"date-time":"2020-06-14T00:00:00Z","timestamp":1592092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1038\/s41375-020-0926-6","type":"journal-article","created":{"date-parts":[[2020,6,14]],"date-time":"2020-06-14T16:02:14Z","timestamp":1592150534000},"page":"468-475","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Reduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis"],"prefix":"10.1038","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8357-7192","authenticated-orcid":false,"given":"Giovanni","family":"Barosi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1862-8168","authenticated-orcid":false,"given":"Paolo","family":"Catarsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Villani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Abb\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Carolei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Magrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Massa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Campanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,14]]},"reference":[{"key":"926_CR1","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","volume":"123","author":"R Rampal","year":"2014","unstructured":"Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel JP, Brunel J-P, Mermel CH, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014;123:e123\u2013e133.","journal-title":"Blood."},{"key":"926_CR2","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","volume":"379","author":"J Grinfeld","year":"2018","unstructured":"Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, et al. Classification and Personalized Prognosis in Myeloproliferative Neoplasms. N. Engl J Med. 2018;379:1416\u201330.","journal-title":"N. Engl J Med"},{"key":"926_CR3","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1182\/blood.2019000162","volume":"134","author":"TN Rao","year":"2019","unstructured":"Rao TN, Hansen N, Hilfiker J, Rai S, Majewska J-M, Lekovic D, et al. JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. Blood. 2019;134:1832\u201346.","journal-title":"Blood."},{"key":"926_CR4","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1158\/0008-5472.CAN-18-1544","volume":"79","author":"C Travelli","year":"2019","unstructured":"Travelli C, Consonni FM, Sangaletti S, Storto M, Morlacchi S, Grolla AA, et al. Nicotinamide phosphoribosyltransferase acts as a metabolic gate for mobilization of myeloid-derived suppressor cells. Cancer Res. 2019;79:1938\u201351.","journal-title":"Cancer Res"},{"key":"926_CR5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/ajh.24388","volume":"91","author":"V Rosti","year":"2016","unstructured":"Rosti V, Campanelli R, Massa M, Viarengo G, Villani L, Poletto V, et al. Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis. Am J Hematol. 2016;91:709\u201313.","journal-title":"Am J Hematol"},{"key":"926_CR6","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.bcmd.2007.01.003","volume":"38","author":"V Rosti","year":"2007","unstructured":"Rosti V, Massa M, Vannucchi AM, Bergamaschi G, Campanelli R, Pecci A, et al. The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells Mol Dis. 2007;38:280\u20136.","journal-title":"Blood Cells Mol Dis"},{"key":"926_CR7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1634\/stemcells.2006-0351","volume":"25","author":"P Guglielmelli","year":"2007","unstructured":"Guglielmelli P, Zini R, Bogani C, Salati S, Pancrazzi A, Bianchi E, et al. Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms\u2019 tumor gene 1 (WT1). Stem Cells. 2007;25:165\u201373.","journal-title":"Stem Cells."},{"key":"926_CR8","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.exphem.2007.10.001","volume":"36","author":"AR Migliaccio","year":"2008","unstructured":"Migliaccio AR, Martelli F, Verrucci M, Migliaccio G, Vannucchi AM, Ni H, et al. Altered SDF-+1\/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease. Exp Hematol. 2008;36:158\u201371.","journal-title":"Exp Hematol."},{"key":"926_CR9","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1634\/stemcells.2008-0377","volume":"26","author":"C Bogani","year":"2008","unstructured":"Bogani C, Ponziani V, Guglielmelli P, Desterke C, Rosti V, Bosi A, et al. Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. Stem Cells. 2008;26:1920\u201330.","journal-title":"Stem Cells"},{"key":"926_CR10","first-page":"5219","volume":"35","author":"A Livun","year":"2015","unstructured":"Livun A, Newberry KJ, Manshouri T, Kusec R, Verstovsek S. Genes involved in maintaining the bone marrow stroma are dysregulated in patients with myelofibrosis: lenalidomide treatment up-regulates SOCS3. Anticancer Res. 2015;35:5219\u201323.","journal-title":"Anticancer Res."},{"key":"926_CR11","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1182\/blood.V98.12.3249","volume":"98","author":"G Barosi","year":"2001","unstructured":"Barosi G, Viarengo G, Pecci A, Rosti V, Piaggio G, Marchetti M, et al. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood. 2001;98:3249\u201355.","journal-title":"Blood."},{"key":"926_CR12","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895\u2013901.","journal-title":"Blood."},{"key":"926_CR13","unstructured":"Swerdlow-SH, Campo E, Harris NL, et al. (Eds): WHO classification of tumours of haematopoietic and lymphoid tissues (Revised 4th edition). IARC: Lyon; 2017."},{"key":"926_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.leukres.2010.07.019","volume":"35","author":"RA Mesa","year":"2011","unstructured":"Mesa RA, Green A, Barosi G, Verstovsek S, Vardiman J, Gale RP. MPN-associated myelofibrosis (MPN-MF). Leuk Res. 2011;35:12\u201313.","journal-title":"Leuk Res."},{"key":"926_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1365-2141.2008.07428.x","volume":"144","author":"JP Salim","year":"2009","unstructured":"Salim JP, Goette NP, Lev PR, Chazarreta CD, Heller PG, Alvarez C, et al. Dysregulation of stromal derived factor 1\/CXCR4 axis in the megakaryocytic lineage in essential thrombocythemia. Br J Haematol. 2009;144:69\u201377.","journal-title":"Br J Haematol"},{"key":"926_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.leukres.2017.06.004","volume":"60","author":"G Barosi","year":"2017","unstructured":"Barosi G, Massa M, Campanelli R, Fois G, Catarsi P, Viarengo G, et al. Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease. Leuk Res. 2017;60:18\u201323.","journal-title":"Leuk Res."},{"key":"926_CR17","doi-asserted-by":"publisher","unstructured":"Barosi G, Campanelli R, Catarsi P, De Amici M, Abb\u00e0 C, Viarengo G, et al. Plasma sIL-2R\u03b1 levels are associated with disease progression in myelofibrosis with JAK2V617F but not CALR mutation. Leuk Res. 2020;90. https:\/\/doi.org\/10.1016\/j.leukres.2020.106319.","DOI":"10.1016\/j.leukres.2020.106319."},{"key":"926_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.exphem.2019.09.025","volume":"79","author":"S McPherson","year":"2019","unstructured":"McPherson S, Greenfield G, Andersen C, Grinfeldc J, Hasselbalch HC, Nangalia Y, et al. Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat. Exp Hematol. 2019;79:26\u201334.","journal-title":"Exp Hematol."},{"key":"926_CR19","doi-asserted-by":"publisher","first-page":"10739","DOI":"10.18632\/oncotarget.7639","volume":"7","author":"AD Whetton","year":"2016","unstructured":"Whetton AD, Azmi NC, Pearson S, Jaworska E, Zhang L, Blance R, et al. MPL W515L expression induces TGF\u03b2 secretion and leads to an increase in chemokinesis via phosphorylation of THOC5. Oncotarget. 2016;7:10739\u201355.","journal-title":"Oncotarget."},{"key":"926_CR20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/PAI.0000000000000391","volume":"26","author":"H Sakr","year":"2018","unstructured":"Sakr H, Clark Schneider K, Murugesan G, Bodo J, Hsi ED, Cook JR. pSTAT3\/pSTAT5 signaling patterns in molecularly defined subsets of myeloproliferative neoplasms. Appl Immunohistochem Mol Morphol. 2018;26:147\u201352.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"926_CR21","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1182\/blood-2007-05-089003","volume":"110","author":"R Chalign\u00e9","year":"2007","unstructured":"Chalign\u00e9 R, James C, Tonetti C, Besancenot R, Le Coue JC, Fava F, et al. Evidence for MPL W515L\/K mutations in hematopoietic stem cells in primitive myelofibrosis. Blood. 2007;110:3735\u201343.","journal-title":"Blood."},{"key":"926_CR22","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1365-2141.2007.06565.x","volume":"137","author":"P Guglielmelli","year":"2007","unstructured":"Guglielmelli P, Pancrazzi A, Bergamaschi G, Rosti V, Villani L, Antonioli E, et al. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol. 2007;137:244\u20137.","journal-title":"Br J Haematol"},{"key":"926_CR23","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1182\/blood-2008-01-135897","volume":"112","author":"AM Vannucchi","year":"2008","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, Pancrazzi A, Guerini V, Barosi G, et al. Characteristics and clinical correlates of MPL 515W>L\/K mutation in essential thrombocythemia. Blood. 2008;112:844\u20137.","journal-title":"Blood."},{"key":"926_CR24","doi-asserted-by":"publisher","first-page":"9448","DOI":"10.1073\/pnas.95.16.9448","volume":"95","author":"Q Ma","year":"1998","unstructured":"Ma Q, Jones D, Borghesani PR, Segal RA, Nagasawa T, Kishimoto T, et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci USA. 1998;95:9448\u201353.","journal-title":"Proc Natl Acad Sci USA"},{"key":"926_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/srep37827","volume":"6","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, D\u00e9pond M, He L, Foudi A, Kwarteng EO, Lauret E, et al. CXCR4\/CXCL12 axis counteracts hematopoietic stem cell exhaustion through selective protection against oxidative stress. Sci Rep. 2016;6:37827.","journal-title":"Sci Rep."},{"key":"926_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.105","volume":"7","author":"E Panieri","year":"2016","unstructured":"Panieri E, Santoro MM. ROS homeostasis and metabolism: a dangerous liason in cancer cells. Cell Death Dis. 2016;7:e2253.","journal-title":"Cell Death Dis"},{"key":"926_CR27","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.cell.2018.08.027","volume":"174","author":"SF Bakhoum","year":"2018","unstructured":"Bakhoum SF, Cantley LC. The multifaceted role of chromosomal instability in cancer and its microenvironment. Cell. 2018;174:1347\u201360.","journal-title":"Cell."}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0926-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0926-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0926-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:41:09Z","timestamp":1684618869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0926-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,14]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["926"],"URL":"https:\/\/doi.org\/10.1038\/s41375-020-0926-6","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,14]]},"assertion":[{"value":"20 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}